Soft tissue sarcomas (STS) are rare, but potentially lethal, extraskeletal mesenchymal neoplasms. It is estimated that approximately 12,000 cases of STS are reported annually in the United States, with 3,500…
In 2002, the fellows and staff at Memorial Sloan-Kettering put together an issue of Surgical Oncology Clinics of North America on randomized clinical trials in oncology. At that time, I…
Pancreatic adenocarcinoma (PDA) is a highly lethal and aggressive malignancy with high mortality rates. It is critical to evaluate novel therapeutic strategies and targets for the treatment of this disease….
Pancreatic adenocarcinoma (PDA) is one of the cancers that is resistant to most conventional anticancer therapies. PDA-affected patients show a poor prognosis. The 5-year survival rate for PDA is 5%…
Neoadjuvant treatment in patients with pancreatic cancer has increased the efficiency of surgery and improved patients’ response to radiotherapy. It has also been shown to expose previously occult metastatic disease…
Adjuvant therapy for pancreatic cancer remains a controversial topic, with a paucity of randomized controlled trials in this area and various limitations in the trials that have been conducted to…
Borderline resectable pancreatic cancer is an emerging stage of disease defined by computed tomogrpahy criteria, patient (Katz type B), or disease characteristics (Katz type C). These patients are particularly well…
Variability exists in the quality of pancreatic cancer care provided in the United States. High-volume centers have been shown to have improved outcomes for pancreatectomy. Regionalization of pancreatic cancer care…
The rapid growth of minimally invasive technology and experience in recent decades has revolutionized many aspects of oncologic surgery. Adoption of laparoscopic pancreatectomy has been slow due to the inherent…
Pancreatic ductal adenocarcinoma (PDA) is the most common pancreatic malignancy comprising approximately 85% of cases. Many aspects of surgical resection of pancreatic cancer have been evaluated as to their effects…
